Importantly, this is the first therapeutic intervention we have shown to elicit a reduction in T1 of tumours arising in Th-MYCN and Th-MYCN/ALKF1174L mice in the absence of any tumour regression, reinforcing the potential of T1 mapping to provide an early imaging biomarker of effective treatment response in neuroblastoma. The gene discussed is MYCN; the disease is neuroblastoma.